Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to the U.S National Library of Medicine, Desmoid tumors are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000 people worldwide. It is also stated that nearly 900 to 1,500 new cases are registered per year in the United States. Tumors associated with familial adenomatous polyposis (FAP) are less common than sporadic desmoid tumors.

On molecular level, desmoid tumor is characterized by one of the two mutations in the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is detected, especially, when pathological differential diagnosis is difficult.

According to the Desmoid Rare Foundation, individuals within the age group of 15 and 60 are more likely to get affected by this condition. It is also stated that the condition is more prevalent in women than in men (2:1).

For the diagnosis of desmoid tumor there are many non-invasive methods available to detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The actual diagnosis of this tumor can be made only after examining a small piece of the tumor by a trained pathologist.

The symptoms of desmoid tumors include a painless swelling or lump, pain and obstruction of the bowels, limping, pain caused by compressed nerves or muscles, and others.

The most commonly used treatment options for desmoid tumors are anti-inflammatory medication, Chemotherapy, Hormone therapy, and surgery among others. Various new therapies are under investigation such as Angiogenesis inhibitors, and Chemotherapy agents. As mutations in the CTNNB1 gene is found to be most commonly occurring in desmoid tumor. So, it is expected that very soon mutation analysis be used to predict the risk of recurrence and to aid in designing individual therapies.

Notably, the market is expected to expand in the near future due to rising demand of effective chemotherapeutic agents, high unmet needs of current treatment, and increase in research and development expenditure.

Despite these drivers, there are some issues associated with desmoid tumors market. High cost of treatment & management of desmoid tumors and related disorders, and lack of infrastructure in the middle and low income countries may hamper the growth of the market.

It is estimated that desmoid tumors market is expected to grow at a CAGR 4.5% during the forecast period of 2017-2023.

Intended Audience

- Hospitals
• Surgical equipment Companies
• Diagnostic clinics
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Figure: Global Desmoid Tumors Market, By Region Market Share, 2017 (%)

Sources: Annual reports, Press release, White paper, Company presentation

Segmentation
The desmoid tumors market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, others

On the basis of treatment, market is classified into surgery, radiation therapy, anti-inflammatory medication, hormone therapy, chemotherapy, novel molecular-targeted therapy, others. Novel molecular-targeted therapy is further segmented into gleevec based therapy, and sorafenib based therapy

On the basis of end-user, market is segmented into hospital, clinics, and others.

Regional Analysis
The Americas dominate the desmoid tumors market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.

Europe holds the second position in the desmoid tumors market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.

Asia Pacific is the fastest growing desmoid tumors market owing to the huge patient pool and developing healthcare technology.

The Middle East & Africa has the lowest market for desmoid tumors market due to lack of technical knowledge and poor medical facilities.

Key Players
Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others.

Research Methodology
Contents:

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations

Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary research
  3.4 Market Size Estimation

Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
  5.1 Porter's Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Desmoid Tumor Market, by Diagnosis
6.1 Introduction
6.2 Biopsy
6.2.1 Market Estimates & Forecast, 2016 – 2023
6.3 Electron Microscopic Examination
6.3.1 Market Estimates & Forecast, 2016 – 2023
6.4 Immunohistochemical Analysis
6.4.1 Market Estimates & Forecast, 2016 – 2023

Chapter 7. Global Desmoid Tumor Market, by treatment
7.1 Introduction
7.2 Surgery
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Radiation Therapy
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 Anti-Inflammatory Medication
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 Hormone Therapy
7.5.1 Market Estimates & Forecast, 2017 – 2023
7.6 Chemotherapy
7.6.1 Market Estimates & Forecast, 2017 – 2023
7.7 Novel Molecular-Targeted Therapy
7.7.1 Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Desmoid Tumor Market, by End User
8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.3 Clinics
8.3.1 Market Estimates & Forecast, 2017 – 2023
8.4 Others

Chapter 9. Global Desmoid Tumor Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Types Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Novartis AG
11.2.1 Company Overview
11.2.2 Types Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Types Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Bayer AG
11.4.1 Company Overview
11.4.2 Types/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 AbbVie Inc.
11.5.1 Company Overview
11.5.2 Types Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Beckman Coulter Inc.
11.6.1 Company Overview
11.6.2 Types Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Stryker Corporation
11.7.1 Overview
11.7.2 Types Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others

Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Desmoid Tumor industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Desmoid Tumor Industry Synopsis, 2017 – 2023
Table 2 Desmoid Tumor Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Desmoid Tumor Market by Region, 2017 – 2023, (USD Million)
Table 4 Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 5 Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 6 Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 7 North America Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 8 North America Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 9 North America Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 10 US Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 11 US Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 12 US Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 13 Canada Desmoid Tumor market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 Canada Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 15 Canada Desmoid Tumor market by End Users, 2017 – 2023, (USD Million)
Table 16 South America Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 17 South America Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 18 South America Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 19 Europe Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 20 Europe Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 21 Europe Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 22 Western Europe Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 23 Western Europe Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 24 Western Europe Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 25 Eastern Europe Desmoid Tumor market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Eastern Europe Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 27 Eastern Europe Desmoid Tumor Market by End Users, 2017 – 2023, (USD Million)
Table 28 Asia Pacific Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 29 Asia Pacific Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 30 Asia Pacific Desmoid Tumor market by End Users, 2017 – 2023, (USD Million)
Table 31 Middle East & Africa Desmoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)
Table 32 Middle East & Africa Desmoid Tumor Market by Treatment, 2017 – 2023, (USD Million)
Table 33 Middle East & Africa Desmoid Tumor market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Desmoid Tumor Market
Figure 3 Segmentation Market Dynamics for Desmoid Tumor Market
Figure 4 Global Desmoid Tumor market Share, by Diagnosis 2016
Figure 5 Global Desmoid Tumor market Share, by Treatment 2016
Figure 6 Global Desmoid Tumor market Share, by End Users, 2016
Figure 7 Global Desmoid Tumor market Share, by Region, 2016
Figure 8 North America Desmoid Tumor market Share, by Country, 2016
Figure 9 Europe Desmoid Tumor market Share, by Country, 2016
Figure 10 Asia Pacific Desmoid Tumor market Share, by Country, 2016
Figure 11 Middle East & Africa Desmoid Tumor market Share, by Country, 2016
Figure 12 Global Desmoid Tumor market: Company Share Analysis, 2016 (%)
Figure 13 Amgen Inc.: Key Financials
Figure 14 Amgen Inc.: Segmental Revenue
Figure 15 Amgen Inc.: Geographical Revenue
Figure 16 Novartis AG: Key Financials
Figure 17 Novartis AG: Segmental Revenue
Figure 18 Novartis AG: Geographical Revenue
Figure 19 Abbott Laboratories: Key Financials
Figure 20 Abbott Laboratories: Segmental Revenue
Figure 21 Abbott Laboratories: Geographical Revenue
Figure 22 Bayer AG: Key Financials
Figure 23 Bayer AG: Segmental Revenue
Figure 24 Bayer AG: Geographical Revenue
Figure 25 AbbVie Inc.: Key Financials
Figure 26 AbbVie Inc.: Segmental Revenue
Figure 27 AbbVie Inc. Geographical Revenue
Figure 28 Beckman Coulter Inc.: Key Financials
Figure 29 Beckman Coulter Inc.: Segmental Revenue
Figure 30 Beckman Coulter Inc.: Geographical Revenue
Figure 31 Stryker Corporation: Key Financials
Figure 32 Stryker Corporation: Segmental Revenue
Figure 33 Stryker Corporation: Geographical Revenue